Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ola Landgren

Showing results (91-100 of 519) with videos related to

Pageof 52
Sort By:
Seminars in Hematology|January 15, 2011
Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significanceSigurdur Yngvi Kristinsson, Magnus Björkholm, Sam Schulman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Survival patterns in patients with Hodgkin's lymphoma with a pre-existing hospital discharge diagnosis of autoimmune diseaseOla Landgren, Ruth M Pfeiffer, Sigurdur Y Kristinsson, et al.
Seminars in Hematology|January 15, 2011
Molecular imaging in myeloma precursor diseaseEsther Mena, Peter Choyke, Esther Tan, et al.
Leukemia & Lymphoma|September 28, 2011
Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expressionPrashant Tembhare, Constance Yuan, Neha Korde, et al.
Seminars in Hematology|January 15, 2011
Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunitiesAlex R Minter, Haley Simpson, Brendan M Weiss, et al.
Blood|July 23, 2013
No familial aggregation in chronic myeloid leukemiaMagnus Björkholm, Sigurdur Y Kristinsson, Ola Landgren, et al.
The Lancet. Oncology|December 3, 2020
Treatments for newly diagnosed multiple myeloma: when endurance is interruptedOla Landgren, David Siegel, Dickran Kazandjian, et al.
British Journal of Haematology|June 6, 2020
The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?Dickran Kazandjian, Clifton C Mo, Ola Landgren, et al.
Current Oncology Reports|April 27, 2024
Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and OpinionsMina Meseha, James Hoffman, Dickran Kazandjian, et al.
Cancer Journal (Sudbury, Mass.)|April 25, 2009
Current insight on trends, causes, and mechanisms of Hodgkin's lymphomaNeil E Caporaso, Lynn R Goldin, William F Anderson, et al.
Pageof 52

Showing results (91-100 of 519) with videos related to

Sort By:
Pageof 52
Seminars in Hematology|January 15, 2011
Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significanceSigurdur Yngvi Kristinsson, Magnus Björkholm, Sam Schulman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Survival patterns in patients with Hodgkin's lymphoma with a pre-existing hospital discharge diagnosis of autoimmune diseaseOla Landgren, Ruth M Pfeiffer, Sigurdur Y Kristinsson, et al.
Seminars in Hematology|January 15, 2011
Molecular imaging in myeloma precursor diseaseEsther Mena, Peter Choyke, Esther Tan, et al.
Leukemia & Lymphoma|September 28, 2011
Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expressionPrashant Tembhare, Constance Yuan, Neha Korde, et al.
Seminars in Hematology|January 15, 2011
Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunitiesAlex R Minter, Haley Simpson, Brendan M Weiss, et al.
Blood|July 23, 2013
No familial aggregation in chronic myeloid leukemiaMagnus Björkholm, Sigurdur Y Kristinsson, Ola Landgren, et al.
The Lancet. Oncology|December 3, 2020
Treatments for newly diagnosed multiple myeloma: when endurance is interruptedOla Landgren, David Siegel, Dickran Kazandjian, et al.
British Journal of Haematology|June 6, 2020
The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?Dickran Kazandjian, Clifton C Mo, Ola Landgren, et al.
Current Oncology Reports|April 27, 2024
Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and OpinionsMina Meseha, James Hoffman, Dickran Kazandjian, et al.
Cancer Journal (Sudbury, Mass.)|April 25, 2009
Current insight on trends, causes, and mechanisms of Hodgkin's lymphomaNeil E Caporaso, Lynn R Goldin, William F Anderson, et al.
Pageof 52